Meeting
2017 ASCO Annual Meeting
GMI-1271, a novel E-selectin antagonist, in combination with chemotherapy in relapsed/refractory AML.
Authors
Daniel J. DeAngelo
Dana-Farber Cancer Institute, Boston, MA
Daniel J. DeAngelo , Brian Andrew Jonas , Jane Liesveld , Michael O'Dwyer , Dale Bixby , Anjali S. Advani , Paula Marlton , John Magnani , Helen M. Thackray , Pamela S. Becker
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics
Track
Developmental Therapeutics and Translational Research
Sub Track
Other Novel Agents
Clinical Trial Registration Number
NCT02306291
Citation
J Clin Oncol 35, 2017 (suppl; abstr 2520)
DOI
10.1200/JCO.2017.35.15_suppl.2520
Abstract #
2520
Poster Bd #
12
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
A phase III trial to evaluate the efficacy of uproleselan (GMI-1271) with chemotherapy in patients with relapsed/refractory acute myeloid leukemia.
First Author: Daniel J. DeAngelo
Poster
2018 ASCO Annual Meeting
Phase 1 study of selinexor plus mitoxantrone, etoposide, and cytarabine in acute myeloid leukemia.
First Author: Bhavana Bhatnagar
Poster
2024 ASCO Breakthrough
Outcome analysis of autologous stem cell transplantation in refractory and relapsed Hodgkin lymphoma: Insights from a North African single-institution study.
First Author: Marouane Maaroufi
Poster
2021 ASCO Annual Meeting
Update of a phase II, multicenter study of high-dose chemotherapy with autologous stem cell transplant followed by maintenance romidepsin for T-cell lymphoma.
First Author: Niloufer Khan